Jim Tananbaum is a successful entrepreneur and venture capital partner. He is the founder and CEO of Foresite Capital, a venture capital firm that focuses on the healthcare industry. The CEO recently announced the addition of Dr. Molly He to the company. Dr. He is a renowned scientific researcher with extensive experience in pharmaceuticals and genome sequencing systems. She joins Foresite Capital as a Venture Partner.
Dr. He previously served as a Director at Illumina, a biotech company involved in sequencing technologies. She has also worked for Pacific Biosciences. Dr. Molly He graduated from Nankai University as well as from the University of California.
She has an in-depth understanding of antibody structures and small molecule drugs. She holds over twenty issued and pending patents in genome sequencing and custom therapies. She has also published numerous medical journals on the subject. Dr. Molly He is proud to join Foresite Capital. She is honored to be part of the team enabling exceptional drug discovery and next-generation therapy options.
Foresite Capital was founded in 2011 and is based in San Francisco, California. Under the stellar leadership of Jim Tananbaum, the company successfully raised over $850 million in venture capital funding between 2013 and 2015. The company’s conspicuous footprint in the healthcare industry includes interests in biotechnology, medical devices, pharmaceuticals, and diagnostics and healthcare services. See, https://inc42.com/buzz/forbes-midas-top-100-investors-2017/.
Foresite Capital has provided venture capital to numerous pharmaceutical and biotechnology companies. Some of these include Tarsa Therapeutics, Intarcia, Aimmune Therapeutics, 10X Genomics and Solid Biosciences among numerous other firms.
As the CEO of Foresite Capital, Jim Tananbaum has overseen numerous venture capital investments in the healthcare industry. He has more than twenty-five years of investing experience in biotech and pharmaceuticals. He has been involved in the establishment and running of numerous companies such as GelTex Pharmaceuticals, Sierra Ventures, Theravance and Prospect Venture Partners.
He has served on the board of Tarsa Therapeutics and Yale School of Engineering. Jim Tananbaum attended Harvard Business School, Yale University, Harvard Medical School and MIT. He has significant interests in Jazz Pharmaceuticals, Amira Pharmaceuticals, and Amerigroup among others. He continues to empower innovative companies with disruptive products to become leaders in the healthcare industry.
Source: Linked In